

Faron Pharmaceuticals Ltd

16:55 11 Apr 2019

Faron to target colorectal cancer patients in ongoing Clevegen study after early promise

Faron Pharmaceuticals Ltd (LON:FARN) is to target more patients with late-stage colorectal cancer as part of the ongoing phase I/II study of its Clevegen immunotherapy drug.

Cancer cells are notoriously good at evading detection by the immune system, but Clevegen has been designed to recognise the tumour cells and break their protective shell.

READ: Faron Pharma up on cancer trial positive

One of the patients currently enrolled in the trial has the most common form of colorectal cancer - called MSI-low - and has seen a "significant shrinkage" in lung metastasis.

That person, who has been treated with six other treatments in the past without success, has also shown further signs of their immune system starting to get to grips with the disease.

Although the three other patients have also reacted well to Clevegen so far and demonstrated an 'immune switch', Faron wants to narrow its focus on MSI-low colorectal patients going forward.

Most likely to respond

"With this patient demonstrating a clinical partial response and expected immune switch, Faron is confident it has identified one group of patients who are thought to most likely respond to treatment and demonstrate an immune switch in these immunosuppressive Clever-1-positive tumour associated macrophages (TAMs)."

MSI-low colorectal patients represent around 90% of all colorectal cancers and there are over one million new cases of the disease around the world every year.

More of those patients will be enrolled into the trial once Faron has figured out the optimal dose of Clevegen.

It has given the four recruited subjects doses of 0.3mg/kg and 1.0mg/kg without any problems, and it has now upped this to 3.0mg/kg.

Assuming that is also well tolerated, the plan is to move up to 10.0mg/kg, which will be the maximum dose.

Boss 'encouraged' by early data

"We are encouraged by the data gathered so far from the MATINS study, particularly the tumour imaging report from a colorectal patient in whom all other treatments have failed, which demonstrates a partial response according to RECIST already in nine weeks," said chief executive Markku Jalkanen.

Price: 297.5

Market Cap: £128.79 m

1 Year Share Price Graph



December 2018 June 2019 December 2019

Share Information

Code: FARN

Listing: AIM

52 week High Low
320.5 50.04

Sector: Pharma & Biotech

Website: www.faron.com

Company Synopsis:

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

action@proactiveinvestors.com.au

"This information further supports our belief that Clevegen has the ability to function as a novel macrophage checkpoint immunotherapy for patients with currently untreatable solid cancers."

He added: "Advancing MATINS into the cohort expansion stage later this year indicates our commitment to rapidly advance the development of this potential therapy for patients in need of new treatment options."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).